SER
Serina Therapeutics, Inc.
There isn't enough reported data to score SER yet.
SER Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SER's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
SER PE Valuation
SER has no meaningful PE right now: it lost money over the past year.
SER Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SER's losses to shrink, with revenue holding steady.
SER Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.75 | +$0.10 |
| Q2 2026 | -$1.89 | -$0.62 |
| Q1 2026 | -$2.00 | -$1.90 |
| Q4 2025 | -$1.91 | +$1.08 |
| Q3 2023 | -$13.13 | -$4.20 |
| Q2 2023 | -$10.27 | -$1.70 |
| Q1 2023 | -$10.27 | -$1.70 |
| Q4 2022 | -$9.69 | -$1.48 |
SER is still losing money, but far less than before: $1.75 per share over the past year, against $13.13 at its worst in late 2023.
SER Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $130K | +155% |
| Q3 2024 | $14K | -79% |
| Q2 2024 | $51K | +467% |
| Q1 2024 | $5K | -50% |
| Q4 2023 | $56K | +600% |
| Q3 2023 | $67K | +644% |
| Q2 2023 | $9K | -25% |
| Q1 2023 | $10K | +100% |
SER's revenue fell from its 2019 peak and has held roughly level since: $125,000 last quarter, down 3.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6289% | N/A |
| Q2 2025 | -4281% | +3300 points |
| Q3 2024 | -37943% | -34426 points |
| Q2 2024 | -7580% | +13375 points |
| Q1 2024 | -46420% | -24840 points |
| Q4 2023 | -6227% | +16048 points |
| Q3 2023 | -3516% | +13706 points |
| Q2 2023 | -20956% | -7697 points |
SER's operating margin was −6289% last quarter, up 40131 points from the same quarter a year ago.
SER Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.5M | -$1.6M |
| Q2 2026 | -$6.7M | -$2.9M |
| Q1 2026 | -$4.6M | -$271K |
| Q4 2025 | -$6M | -$1.4M |
| Q3 2025 | -$3.9M | -$898K |
| Q2 2025 | -$3.8M | +$4.2M |
| Q1 2025 | -$4.3M | -$2.7M |
| Q4 2024 | -$4.6M | -$2.5M |
SER has burned cash in almost every quarter: −$23M over the past year, against −$17M the year before.
SER Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +55% | +9M shares |
| 1 year | +146% | +15.1M shares |
| 3 years | +2292% | +24.4M shares |
SER has 25M diluted shares, up 146% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
SER Net Leverage
SER's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SER Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.3 | Neutral |
| Stochastic | 23.0 | Neutral |
SER's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
SER PE vs Healthcare Sector
SER has no meaningful PE right now: it lost money over the past year.
SER Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.77 | 20% below |
| 20 week MA | $2.11 | 33% below |
| 50 week MA | $2.16 | 35% below |
| 100 week MA | $3.68 | 62% below |
| 200 week MA | $9.95 | 86% below |
SER is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
SER Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.1 | $59.3 | -4.6% |
| 2021 | $59.3 | $21.4 | -64% |
| 2022 | $21.4 | $19.6 | -8.4% |
| 2023 | $19.6 | $13.8 | -30% |
| 2024 | $13.8 | $5.64 | -59% |
| 2025 | $5.64 | $2.66 | -53% |
| 2026 YTD | $2.66 | $1.41 | -47% |
SER has finished every year since 2020 lower, and it's down 47% so far in 2026.